Fast forward: fibroid management in 2042
Looking into the Crystal Ball
VOLUME 2, ISSUE 2, P114-115, MAY 01, 2021
Malak El Sabeh, M.D., Mostafa A. Borahay, M.D., Ph.D., M.B.A.
It is January 5, 2042. I did not have surgeries this week, only office visits, teaching, and research. The first patient scheduled in the clinic today was a 42-year-old lady with a body mass index of 34 kg/m2 and a history of hypertension. She initially presented for heavy periods and pelvic pain. Imaging revealed several small fibroids, and her laboratory results showed elevated cholesterol and triglycerides. Her fibroid biomarkers suggested that her metabolic disorders were contributing to the development of her fibroids. I discussed the findings with her, recommended lifestyle changes, and started her on simvastatin. I also started her on an angiotensin-converting enzyme (ACE) inhibitor for her elevated blood pressure.